(NASDAQ: APVO) Aptevo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 4.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.01%.
Aptevo Therapeutics's earnings in 2025 is -$24,025,000.On average, 1 Wall Street analyst forecast APVO's earnings for 2025 to be -$46,622,677, with the lowest APVO earnings forecast at -$46,622,677, and the highest APVO earnings forecast at -$46,622,677. On average, 1 Wall Street analyst forecast APVO's earnings for 2026 to be -$24,396,352, with the lowest APVO earnings forecast at -$24,396,352, and the highest APVO earnings forecast at -$24,396,352.
In 2027, APVO is forecast to generate -$23,574,372 in earnings, with the lowest earnings forecast at -$23,574,372 and the highest earnings forecast at -$23,574,372.